替雷利珠单抗联合化疗治疗三阴性乳腺癌的临床观察

Clinical Observation of the Treatment of Triple Negative Breast Cancer with the Combination of the Tislelizumab and the Chemotherapy

摘要: 目的：探讨替雷利珠单抗联合化疗治疗局部晚期/晚期三阴性乳腺癌的获益与风险。方法：采用回顾性研究，收集2020年10月至2021年9月烟台毓璜顶医院收治的20例局部晚期/晚期三阴性乳腺癌患者，10例应用替雷利珠单抗联合化疗，10例标准化疗，比较两组临床疗效、不良反应发生率及治疗前后肿瘤标志物水平。结果：研究组总缓解率30%、疾病控制率70%均高于对照组的0%、40%，差异均具有统计学意义(P < 0.05)。治疗相关不良反应发生率为80.0% (8/10)，不良反应以1~2级为主，≥3级不良反应发生率为20.0% (2/10)；研究期间，无患者死亡。结论：对于局部晚期/晚期三阴性乳腺癌患者，替雷利珠单抗联合化疗不失为一种好的选择，在有效控制疾病进展同时，可降低肿瘤标志物水平。

Abstract: OBJECTIVE: To investigate the benefits and risks of tislelizumab in combination with chemotherapy for locally advanced/advanced triple-negative breast cancer. METHODS: A retrospective study was conducted to collect 20 patients with locally advanced/advanced triple-negative breast cancer admitted to Yantai Yuhuangding Hospital from October 2020 to September 2021, 10 patients were treated with tislelizumab combined with chemotherapy and 10 patients were treated with standard chemotherapy. The clinical efficacy, incidence rate of adverse reactions and tumor marker levels before and after treatment were compared between the two groups. RESULTS: The overall response rate (ORR) of 30% and disease control rate (DCR) of 70% in study group were higher than those of 0% and 40% in control group, and the differences had statistical significance (P < 0.05). The incidence of treatment-related adverse reactions was 80.0% (8/10). The adverse reactions were mainly grade 1~2. The incidence of grade ≥ 3 adverse reactions was 20.0% (2/10). No patient died during the study. CONCLUSION: For patients with locally advanced/advanced triple-negative breast cancer, the combination of tislelizumab and chemotherapy is a good option to effectively control disease progression while reducing tumor marker levels.